Aardvark Therapeutics, Inc. Common Stock
AARD
NASDAQ·Healthcare·Biotechnology·Mkt cap $125.4M
$5.73
▼ -3.70%
P/E
-1.79
Mkt Cap
$125.4M
52-Wk Range
$3.35–$17.94
52-Week Range
$3.35 - $17.94
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 32.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary gut receptor targeting technology
- Advanced small-molecule therapeutic platform
- Focused clinical development strategy
- Innovative approach to metabolic disease treatment
Bear Case
1 risk
- Very high volatility (beta 3.7). Expect 3x market swings. Position size accordingly.
Growth
Stable outlook
Advancing ARD-101 clinical trials
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+45.4% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying AARD right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 12, 2026
AUG 11, 2026
Reported EPS of -$0.66 vs -$0.87 consensus (+24.5% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+24.5%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
3 analysts · 33% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
33%
Hold
33%
Sell
33%
Median Price Target
—
Latest: B. Riley · May 15, 2026
vs Industry
How AARD stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related